ACA’s Pricing, Formulary Pressures to Force Pipeline Reform, Push Novel Drugs

A A
While the 2010 Affordable Care Act (ACA) is generally a revenue boon for drugmakers, the law presents pricing and formulary pressures that will force companies to steer toward less-saturated disease areas and better show the value of their products, experts say.

To View This Article:

Login

Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $25.00